Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Jennifer Trujillo to Insulin

This is a "connection" page, showing publications Jennifer Trujillo has written about Insulin.

 
Connection Strength
 
 
 
1.077
 
  1. Patel D, Triplitt C, Trujillo J. Appropriate Titration of Basal Insulin in Type 2 Diabetes and the Potential Role of the Pharmacist. Adv Ther. 2019 05; 36(5):1031-1051.
    View in: PubMed
    Score: 0.326
  2. Johnson EL, Frias JP, Trujillo JM. Anticipatory guidance in type 2 diabetes to improve disease management; next steps after basal insulin. Postgrad Med. 2018 May; 130(4):365-374.
    View in: PubMed
    Score: 0.304
  3. Trujillo JM, Barsky EE, Greenwood BC, Wahlstrom SA, Shaykevich S, Pendergrass ML, Schnipper JL. Improving glycemic control in medical inpatients: a pilot study. J Hosp Med. 2008 Jan; 3(1):55-63.
    View in: PubMed
    Score: 0.150
  4. Doyle-Delgado K, Chamberlain JJ, Shubrook JH, Skolnik N, Trujillo J. Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline. Ann Intern Med. 2020 11 17; 173(10):813-821.
    View in: PubMed
    Score: 0.090
  5. Thompson AM, Trujillo JM. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes. Ann Pharmacother. 2015 Mar; 49(3):351-9.
    View in: PubMed
    Score: 0.061
  6. Trujillo JM, Nuffer W. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy. 2014 Nov; 34(11):1174-86.
    View in: PubMed
    Score: 0.060
  7. Nuffer W, Trujillo JM, Ellis SL. Technosphere insulin (Afrezza): a new, inhaled prandial insulin. Ann Pharmacother. 2015 Jan; 49(1):99-106.
    View in: PubMed
    Score: 0.060
  8. Wright EE, Malone DC, Trujillo JM, Gill J, Huse S, Li X, Zhou FL, Preblick R, Reid T. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin. J Manag Care Spec Pharm. 2022 Jun; 28(6):592-603.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)